ESMO 2023 | Treatment guidelines for non-oncogene-addicted metastatic NSCLC

Marco Tagliamento, MD, Gustave Roussy, Villejuif, France, provides an overview of recommended treatment strategies for non-oncogene-addicted metastatic non-small cell lung cancer (NSCLC). The current standard of care is anti-PD-(L)1 therapies and Dr Tagliamento further discusses how clinicians can effectively manage oligoprogressive disease, as well as the optimal duration of first line immunotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.